JP7761374B2 - Method for suppressing the adhesion of harmful substances to the atmosphere - Google Patents

Description

The present invention relates to a method for suppressing the adhesion of atmospheric hazardous substances.

In recent years, harmful substances suspended in the air, such as pollen from cedar and cypress trees, soot, dust, and other air pollutants, as well as yellow sand (hereinafter referred to as "air hazardous substances"), have become a problem due to their various health hazards to humans. Among these air hazardous substances, particulate matter with a diameter of 2.5 μm or less, known as PM2.5, is composed of carbon components, sulfates, nitrates, ammonium salts, and other components. Inhalation of PM2.5 and yellow sand is known to cause circulatory and respiratory diseases. It has also been pointed out that PM2.5, yellow sand, and pollen can cause skin problems by adhering to or penetrating the skin. For example, Non-Patent Document 1 contains an academic report on the damage caused by PM2.5 to the skin. Therefore, there is a growing demand for cosmetics that protect the skin from air hazardous substances.
For example, Patent Document 1 describes a skin care cosmetic that contains a specific amount of magnesium aluminometasilicate and a specific amount of an ultraviolet protection agent as a skin care cosmetic that protects the skin from external stimuli such as air pollutants.

International Publication No. 2014/136993

Shiraiwa et al., Nature Chemistry 3, 291-295 (2011)

The technology of Patent Document 1 describes that magnesium aluminometasilicate adsorbs air pollutants using its adsorption ability to prevent them from reaching the skin, and that even if acidic substances adhere, it can neutralize them using its pH buffering ability, thereby reducing skin damage caused by these external stimuli. It also describes that UV protection agents effectively protect the skin from UV rays. While such technology can reduce the effects of air pollutants on the skin, it does not prevent air pollutants from adhering to the skin, and there is room for improvement. Furthermore, when inorganic powders are incorporated into topical preparations, a poor tactile sensation, such as a squeaky feeling, may occur when the topical preparation is applied to the skin. Therefore, a good usability during application is also required.
The present invention aims to provide a method for inhibiting the adhesion of atmospheric hazardous substances, which provides a good feeling when applied to the skin and can effectively inhibit the adhesion of atmospheric hazardous substances to the skin.

The present inventors have found that the above-mentioned problems can be solved by applying to the skin an external preparation containing a specific mass ratio of a hydrophobized metal oxide having an average primary particle size within a specific range and a non-volatile silicone oil, rather than adsorbing air pollutants as in Patent Document 1. This creates nano-sized irregularities on the skin surface without worsening the feel upon application, thereby suppressing adhesion of air pollutants to the skin.
That is, the present invention provides a method for inhibiting adhesion of atmospheric hazardous substances to the skin by applying an external preparation to the skin, the method comprising:
The topical preparation contains the following components (A) and (B), and the mass ratio of the content of component (B) to the content of component (A) in the topical preparation [(B)/(A)] is 0.85 or less.
Component (A): A hydrophobized metal oxide having an average primary particle diameter d _A of 800 nm or less. Component (B): A non-volatile silicone oil.

The method of the present invention provides a pleasant feel when applied to the skin and effectively prevents air hazardous substances from adhering to the skin.

FIG. 1 is a schematic diagram showing a method for evaluating the effect of suppressing adhesion of atmospheric hazardous substances.

[Method for suppressing adhesion of atmospheric hazardous substances]
The method for inhibiting the adhesion of atmospheric hazardous substances of the present invention is a method for inhibiting the adhesion of atmospheric hazardous substances to the skin by applying an external preparation to the skin, wherein the external preparation contains the following components (A) and (B), and the mass ratio [(B)/(A)] of the content of component (B) to the content of component (A) in the external preparation is 0.85 or less.
Component (A): a hydrophobized metal oxide having an average primary particle diameter d _A of 800 nm or less; Component (B): a non-volatile silicone oil. In the present invention, "harmful air substances" refers to air pollutants such as pollen from cedar, cypress, etc.; soot and smoke such as sulfur oxides, soot and dust, nitrogen oxides, particulate matter, automobile exhaust gases, harmful air pollutants such as benzene, trichloroethylene, tetrachloroethylene, and particles containing volatile organic compounds (VOCs); and harmful substances (including PM2.5) suspended in the air, such as yellow sand.
In the present invention, the term "hydrophobized metal oxide" refers to a metal oxide whose surface has been subjected to a hydrophobization treatment.
In the following description, the effect of the present invention in inhibiting adhesion of atmospheric hazardous substances will be simply referred to as "adhesion inhibiting effect."

The adhesion inhibiting method of the present invention provides a good feeling when applying the topical preparation to the skin and is highly effective in inhibiting the adhesion of air hazardous substances, particularly air hazardous substances in the form of fine particles. The reason for this is not clear, but is thought to be as follows.
In the present invention, by applying to the skin a metal oxide having an average primary particle size within a specific range and whose surface has been hydrophobized, nano-sized irregularities are formed on the skin surface, which reduces the contact area when atmospheric hazardous substances come into contact with the metal oxide, and is thought to effectively suppress the adhesion of atmospheric hazardous substances.
In addition, the topical preparation of the present invention contains hydrophobic metal oxide and non-volatile silicone oil as oil agent in a specific mass ratio, so it is thought that the lubricating effect of this silicone oil can bring about a good feeling of use without hindering the effect of preventing the adhesion of the above-mentioned atmospheric harmful substances.In addition, the hydrophobic metal oxide and this silicone oil can spread smoothly on the skin surface, so it is thought that this can also contribute to a good feeling of use.

<External preparations>
The topical preparation used in the present invention contains the above-mentioned component (A) and component (B) from the viewpoint of improving the adhesion inhibitory effect and improving the feeling of use when applied to the skin.

[Component (A): Hydrophobized Metal Oxide]
Component (A) is a hydrophobized metal oxide (hereinafter also referred to as "hydrophobized metal oxide") having an average primary particle diameter d _A of 800 nm or less.
The average primary particle diameter d _A of component (A) is 800 nm or less, preferably 500 nm or less, more preferably 300 nm or less, even more preferably 200 nm or less, still more preferably 80 nm or less, and even more preferably 50 nm or less from the viewpoint of improving the adhesion suppression effect, and is preferably 5 nm or more, more preferably 10 nm or more from the viewpoint of versatility. More specifically, from the viewpoint of improving the adhesion suppression effect and versatility, the average primary particle diameter d _A is preferably 5 to 800 nm, more preferably 5 to 500 nm, even more preferably 5 to 300 nm, still more preferably 5 to 200 nm, still more preferably 5 to 80 nm, still more preferably 5 to 50 nm, and even more preferably 10 to 50 nm.
The average primary particle diameter d _A in the present invention can be determined from an image observed with a transmission electron microscope (TEM). Specifically, the TEM is used to observe the particles at a magnification of 50,000 times, and the maximum minor axis diameters of 300 primary particles in the observed image are measured and the number average value is calculated. Here, the maximum minor axis diameter refers to the longest minor axis among the minor axes perpendicular to the major axis when component (A) has a shape other than a plate shape. When component (A) is plate-shaped, the thicknesses of 300 primary particles in the observed image observed under the same conditions as above are measured and the number average value is calculated. Specifically, the measurement is performed by the method described in the examples.

The metal oxide of component (A) is not particularly limited as long as it is one that is commonly used in external preparations such as cosmetics. Specific examples include titanium oxide, zinc oxide, cerium oxide, aluminum oxide (alumina), magnesium oxide, calcium oxide, zirconium oxide, iron oxide, and chromium oxide. Among these, from the viewpoint of imparting ultraviolet protection ability, preferably, one or more selected from titanium oxide, zinc oxide, and cerium oxide are used, and more preferably, one or more selected from titanium oxide and zinc oxide.
When the metal oxide of component (A) is titanium oxide, the crystal structure of the titanium oxide may be any of anatase, rutile, and brookite, but from the viewpoint of versatility, the rutile or anatase structure is preferred.

The shape of component (A) may be spherical, spindle-shaped, plate-shaped, needle-shaped, etc. Among these, spherical, spindle-shaped, and plate-shaped shapes are preferred from the viewpoint of improving the adhesion suppression effect.
When the metal oxide of component (A) is titanium oxide, it is preferably spindle-shaped from the viewpoint of improving the adhesion suppression effect.
When the metal oxide of component (A) is zinc oxide, it is preferably spherical or plate-shaped from the viewpoint of improving the adhesion suppression effect.
The component (A) may be present in the form of primary particles or in the form of aggregates (secondary particles) formed by aggregation of primary particles, as long as the average primary particle diameter d _A satisfies the above-mentioned range.

The topical preparation used in the present invention contains the hydrophobized component (A), which improves the dispersibility of component (A) in the topical preparation containing component (B), thereby improving the adhesion-inhibiting effect.
Examples of hydrophobic treatments include fatty acid treatment; alkylalkoxysilane treatment; silicone treatment; treatment with a fluorine-containing compound such as perfluoroalkyl phosphate ester, perfluoroalcohol, or perfluoroalkylalkoxysilane; treatment with an amino acid such as N-acylglutamic acid; and alkyl phosphate ester treatment.
Among these, fatty acid treatment, alkylalkoxysilane treatment, and silicone treatment are preferred from the viewpoint of increasing the dispersibility of component (A) in the topical preparation containing component (B) and improving the adhesion-inhibiting effect.
That is, from the viewpoint of increasing the dispersibility of component (A) in the topical preparation containing component (B) and improving the adhesion-inhibiting effect, component (A) is preferably one or more selected from the following components (A1), (A2), and (A3):
Component (A1): A fatty acid-treated metal oxide having an average primary particle diameter d _{A of 800 nm or less. Component (A2): An alkylalkoxysilane-treated metal oxide having an average primary particle diameter d A of} 800 nm or less. Component (A3): A silicone-treated metal oxide having an average primary particle diameter d _A of 800 nm or less.

Examples of surface treatment agents used in the fatty acid treatment of component (A1) include linear or branched fatty acids having from 12 to 22 carbon atoms. Among these, from the viewpoint of increasing the dispersibility of component (A) in the topical preparation containing component (B) and improving the adhesion-inhibiting effect, linear or branched higher fatty acids having from 14 to 22 carbon atoms are preferred, linear or branched higher fatty acids having from 16 to 20 carbon atoms are more preferred, and stearic acid and isostearic acid are even more preferred.
As the surface treatment agent used for the alkylalkoxysilane treatment of component (A2), from the viewpoint of increasing the dispersibility of component (A) in the topical agent containing component (B) and improving the adhesion suppression effect, one having a linear or branched alkyl group having from 6 to 20 carbon atoms is preferred, and octyltriethoxysilane and octyltrimethoxysilane are more preferred.

Surface treatment agents used in the silicone treatment of component (A3) include various silicone oils such as methylpolysiloxane, dimethylpolysiloxane, methylphenylpolysiloxane, methylhydrogenpolysiloxane, methylcyclopolysiloxane, dodecamethylcyclohexasiloxane, tetradecamethylhexasiloxane, dimethylsiloxane/methyl(polyoxyethylene)siloxane/methyl(polyoxypropylene)siloxane copolymer, dimethylsiloxane/methyl(polyoxyethylene)siloxane copolymer, dimethylsiloxane/methyl(polyoxypropylene)siloxane copolymer, dimethylsiloxane/methylcetyloxysiloxane copolymer, dimethylsiloxane/methylstearoxysiloxane copolymer, and alkyl acrylate/dimethicone copolymer. Among these, methylhydrogenpolysiloxane and dimethylpolysiloxane are preferred from the viewpoint of improving the dispersibility of component (A) in the topical preparation containing component (B) and improving the adhesion-inhibiting effect.

The above-mentioned surface treatment agents may be used alone or in combination of two or more.
The amount of hydrophobic treatment is preferably 0.1% by mass or more, and preferably 40% by mass or less, more preferably 30% by mass or less, relative to component (A), from the viewpoint of increasing the dispersibility of component (A) in the topical preparation containing component (B) and improving the adhesion-inhibiting effect.
In the present invention, the mass, coating amount and average primary particle diameter d _A of component (A) mean the mass, coating amount and average primary particle diameter d _A including the surface treatment agent.

When component (A) is hydrophobized titanium oxide, the content of _TiO2 in the hydrophobized titanium oxide is preferably 60% by mass or more, more preferably 70% by mass or more, and preferably less than 100% by mass, from the viewpoint of improving the adhesion suppression effect.
When component (A) is hydrophobized zinc oxide, the content of ZnO in the hydrophobized zinc oxide is preferably 60% by mass or more, more preferably 70% by mass or more, and preferably less than 100% by mass, from the viewpoint of improving the adhesion suppression effect.

From the viewpoint of improving the dispersibility of component (A) in a topical preparation containing component (B) and improving its adhesion-inhibiting effect, component (A) is preferably one or more selected from fatty acid-treated titanium oxide and fatty acid-treated zinc oxide as component (A1), alkylalkoxysilane-treated titanium oxide and alkylalkoxysilane-treated zinc oxide as component (A2), and silicone-treated titanium oxide and silicone-treated zinc oxide as component (A3); more preferably, component (A1) is one or more selected from fatty acid-treated titanium oxide and fatty acid-treated zinc oxide as component (A2), and alkylalkoxysilane-treated titanium oxide and alkylalkoxysilane-treated zinc oxide as component (A2); and even more preferably, component (A2) is one or more selected from alkylalkoxysilane-treated titanium oxide and alkylalkoxysilane-treated zinc oxide.

Commercially available products of component (A1) include "STR-100C-LF" (stearic acid-treated titanium oxide) manufactured by Sakai Chemical Industry Co., Ltd.; "MPT-171" (stearic acid-treated titanium oxide) manufactured by Ishihara Sangyo Kaisha, Ltd.; and "MT-100TV" (stearic acid-treated titanium oxide) and "MT-100Z" (stearic acid-treated titanium oxide) manufactured by Teika Corporation.
Commercially available products of component (A2) include "STR-100C-OTS" (titanium oxide treated with octyltriethoxysilane), "STR-100W-OTS" (titanium oxide treated with octyltriethoxysilane), "FINEX-50-OTS" (zinc oxide treated with octyltriethoxysilane), and "FINEX-30-OTS" (zinc oxide treated with octyltriethoxysilane), all manufactured by Sakai Chemical Industry Co., Ltd.
Commercially available products of component (A3) include "STR-100A-LP" (silicone-treated titanium oxide) and "FINEX-50-LPTM" (silicone-treated zinc oxide) manufactured by Sakai Chemical Industry Co., Ltd.; "JR-800S" (silicone-treated titanium oxide), "MPY-70M" (silicone-treated titanium oxide), "MICRO ZINC OXIDE MZ-504R3M" (silicone-treated zinc oxide), and "MT-600KS" (silicone-treated zinc oxide) manufactured by Teika Corporation; and "D-FZN" (silicone-treated zinc oxide) manufactured by Daito Kasei Kogyo Co., Ltd.

[Component (B): Non-volatile silicone oil]
Component (B) is an oil agent, which is a non-volatile silicone oil.
In the present invention, "non-volatile" means that the amount of evaporation at 25°C for 6 hours is less than 20%, as measured by the following method.
Measurement method: A 90 mm diameter filter paper is placed in a 120 mm diameter glass dish, 1 g of the sample is placed on the filter paper, and stored in a room at 65% RH (25°C) for 6 hours. The mass of the sample is measured before and after storage, and the amount of evaporation is calculated using the following formula.
Evaporation amount (%) = (sample mass before storage - sample mass after storage) / sample mass before storage x 100

Specific examples of component (B) include linear organopolysiloxanes such as dimethylpolysiloxane, methylphenylpolysiloxane, methylhydrogenpolysiloxane, and dimethiconol (dimethylpolysiloxane blocked at both ends with hydroxy groups); modified silicones such as amino-modified silicones (dimethylpolysiloxanes having amino groups in the molecule) and polyglycerin-modified silicones having branched polyglycerol chains at both ends; amino-derivative silicones; and liquid, semi-solid, and solid silicone oils such as silicone wax. Component (B) can be used singly or in combination of two or more.
Of these, from the viewpoint of providing a good feeling when applied to the skin, linear organopolysiloxanes are preferred, and dimethylpolysiloxanes are more preferred.

From the viewpoint of improving the feel when applied to the skin and improving the adhesion-inhibiting effect, component (B) is preferably a silicone oil having a kinematic viscosity at 25°C of 5 ^mm2 /s or more and 100,000 ^mm2 /s or less.
The kinematic viscosity of component (B) at 25°C is more preferably 6 mm ² /s or more from the viewpoint of improving the feel when applied to the skin, and from the viewpoint of improving the adhesion-inhibiting effect and improving the feel when applied to the skin, it is more preferably 10,000 mm ² /s or less, even more preferably 5,000 mm ² /s or less, even more preferably 1,000 mm ² /s or less, even more preferably 500 mm ² /s or less, even more preferably 300 mm ² /s or less, even more preferably 100 mm ² /s or less, even more preferably 50 mm ² /s or less, and even more preferably 30 mm ² /s or less. More specifically, from the viewpoint of improving the adhesion-inhibiting effect and improving the feel when applied to the skin, the kinematic viscosity of component (B) at 25°C is preferably 5 to 100,000 mm ² /s, more preferably 5 to 10,000 mm ² /s, even more preferably 5 to 5,000 mm ² /s, still more preferably 5 to 1,000 mm ² /s, even more preferably 5 to 500 mm ² /s, still more preferably 5 to 300 mm ² /s, still more preferably 5 to 100 mm ² /s, still more preferably 5 to 50 mm ² /s, still more preferably 5 to 30 mm ² /s, and still more preferably 6 to 30 mm ² /s.
The kinematic viscosity of component (B) at 25° C. can be measured using an Ubbelohde viscometer in accordance with ASTM D 445-46T or JIS Z 8803.
Commercially available products of component (B) include "KF-96A-6cs" (dimethylpolysiloxane) and "KF-96A-10cs" (dimethylpolysiloxane) manufactured by Shin-Etsu Chemical Co., Ltd.

In addition to components (A) and (B), the topical preparation may contain cosmetic or medicinal ingredients used depending on the intended use of the topical preparation, or ingredients commonly used in topical preparations such as skin cosmetics, as appropriate, to the extent that the purpose of the present invention is not impaired. Examples of such ingredients include, in addition to components (A) and (B), oils, antioxidants, UV absorbers, surfactants, thickeners, pH adjusters, disinfectants, anti-inflammatory agents, preservatives, colorants, chelating agents, moisturizers, pearlizing agents, ceramides, antiperspirants, fragrances, etc.

[Component (C): Non-volatile oil other than component (B)]
The topical preparation may further contain a non-volatile oil other than component (B) as component (C). Component (C) may be one or more selected from ester oils, hydrocarbon oils, higher fatty acids, and higher alcohols. Of these, one or more selected from ester oil (C1) (hereinafter also referred to as "component (C1)") and non-volatile hydrocarbon oil (C2) (hereinafter also referred to as "component (C2)") are preferred.

Examples of the component (C1) include synthetic ester oils and natural fats and oils, and specific examples include esters of monocarboxylic acids and monohydric alcohols, esters of monocarboxylic acids and polyhydric alcohols, and esters of polycarboxylic acids and monohydric alcohols.
Examples of the ester of a monovalent carboxylic acid and a monohydric alcohol include esters represented by the following general formula (1).
R ¹ -COO-R ² (1)
In the general formula (1), ^R1 represents a linear or branched alkyl or alkenyl group having 1 to 25 carbon atoms, or an aromatic hydrocarbon group having 6 to 24 carbon atoms, which may be substituted with a hydroxyl group, and ^R2 represents a linear or branched alkyl or alkenyl group having 1 to 30 carbon atoms.

When ^R1 is an alkyl group or an alkenyl group, the number of carbon atoms is preferably 7 or more, more preferably 9 or more, and even more preferably 11 or more, from the viewpoint of improving the feel when applied to the skin, and is preferably 23 or less, more preferably 21 or less, and even more preferably 19 or less, from the same viewpoint as above.
When ^R1 is an aromatic hydrocarbon group, the number of carbon atoms is preferably 8 or more, more preferably 10 or more, from the viewpoint of improving the feel when applied to the skin, and is preferably 22 or less, more preferably 20 or less, from the same viewpoint as above.
The number of carbon atoms in ^R2 is preferably 2 or more from the viewpoint of improving the feel when applied to the skin, and from the same viewpoint as above, is preferably 28 or less, more preferably 20 or less, and even more preferably 18 or less.
In addition, from the viewpoint of improving the feeling when applied to the skin, it is preferable that at least one of R ¹ and R ² is a branched alkyl group.

Specific examples of esters represented by the general formula (1) include myristyl 2-ethylhexanoate, cetyl 2-ethylhexanoate, stearyl 2-ethylhexanoate, isodecyl octanoate, cetyl octanoate, isocetyl octanoate, isononyl isononanoate, isotridecyl isononanoate, hexyldecyl dimethyloctanoate, hexyl laurate, isopropyl myristate, isotridecyl myristate, 2-hexyldecyl myristate, myristyl myristate, octyldodecyl myristate, isopropyl palmitate, 2-ethylhexyl palmitate, 2-hexyldecyl palmitate, Examples include one or more selected from 2-heptylundecyl palmitate, butyl stearate, 2-ethylhexyl stearate, stearyl stearate, isocetyl stearate, cetyl stearate, isocetyl isostearate, cholesteryl isostearate, decyl oleate, oleyl oleate, octyldodecyl oleate, lanolin acetate, cholesteryl hydroxystearate, isopropyl lanolinate, cholesteryl lanolinate, methyl castor oil fatty acid (methyl ricinoleate), cetyl lactate, myristyl lactate, and alkyl benzoate (alkyl having 12 to 15 carbon atoms).

Examples of the ester of a monovalent carboxylic acid and a monohydric alcohol include an ester represented by the following general formula (2).
R ³ -COO-(AO) _n -R ⁴ (2)
In the general formula (2), ^R3 represents a linear or branched alkyl or alkenyl group having from 1 to 25 carbon atoms, which may be substituted with a hydroxyl group, ^R4 represents an aromatic hydrocarbon group having from 6 to 24 carbon atoms, AO represents an alkyleneoxy group having from 2 to 4 carbon atoms, and n represents the average number of moles added of from 1 to 50.
^R3 preferably has 7 or more carbon atoms from the viewpoint of improving the feel when applied to the skin, and from the same viewpoint as above, is an alkyl group having preferably 23 or less, more preferably 21 or less, and even more preferably 19 or less.
From the viewpoint of improving the feel when applied to the skin, ^R4 preferably has 6 or more carbon atoms, and from the same viewpoint as above, it is preferably an aromatic hydrocarbon group having 22 or less, more preferably 20 or less, even more preferably 18 or less, and even more preferably a benzyl group.
The AO group is preferably a propyleneoxy group from the viewpoint of improving the feel when applied to the skin, and from the same viewpoint as above, n is preferably 1 or more and 10 or less, more preferably 1 or more and 5 or less.
Specific examples of the ester represented by the general formula (2) include an ester of myristic acid and a 3-mol propylene oxide adduct of benzyl alcohol ("Crodamol STS" manufactured by Croda), an ester of 2-ethylhexanoic acid and a 3-mol propylene oxide adduct of benzyl alcohol ("Crodamol SFX" manufactured by Croda), and the like.

Examples of the ester of a monovalent carboxylic acid and a polyhydric alcohol include esters represented by the following general formula (3).
R ⁵ - (OCOR ⁶ ) _p (3)
In the general formula (3), ^R5 represents a polyhydric alcohol residue, preferably a linear or branched hydrocarbon group having from 2 to 10 carbon atoms, ^R6 represents a monocarboxylic acid residue having from 1 to 25 carbon atoms, and p represents an integer of from 2 to 10.
^R5 may have an ether bond. Preferably, p is the same number as the number of hydroxy groups in the polyhydric alcohol.
From the viewpoint of improving the feel when applied to the skin, ^R6 preferably has 7 or more carbon atoms, more preferably 9 or more carbon atoms, and even more preferably 11 or more carbon atoms, and from the same viewpoint as above, R6 is an alkyl group having 23 or less carbon atoms, more preferably 21 or less carbon atoms, and even more preferably 19 or less carbon atoms.

Examples of the ester represented by the general formula (3) include neopentyl glycol dicaprate, neopentyl glycol di-2-ethylhexanoate, propanediol di(caprylic/capric acid), propanediol diisostearate, ethylene glycol di-2-ethylhexanoate, glyceryl tri(caprylic/capric acid), glyceryl tri-2-ethylhexanoate, glyceryl tri-2-heptylundecanoate, glyceryl trimyristate, trimethylolpropane tri-2-ethylhexanoate, trimethylolpropane triisostearate, pentaerythritol tetra-2-ethylhexanoate, fatty acid dipentaerythritol, and natural fats and oils.
Examples of natural oils include castor oil, cacao oil, mink oil, avocado oil, olive oil, sunflower oil, camellia oil, apricot kernel oil, almond oil, wheat germ oil, Theobroma grandiflorum seed oil, grape seed oil, babassu oil, jojoba oil, macadamia nut oil, camellia sinensis oil, shea butter oil, camellia recutita seed oil, and meadowfoam oil.

Examples of the ester of a polycarboxylic acid and a monohydric alcohol include an ester represented by the following general formula (4).
R ⁷ -(COOR ⁸ ) _q (4)
In the general formula (4), ^R7 represents a polycarboxylic acid residue having from 2 to 10 carbon atoms, ^R8 represents a monohydric alcohol residue having from 1 to 25 carbon atoms, and q represents an integer of from 2 to 10. Preferably, q is the same number as the number of carboxy groups in the polycarboxylic acid.
^R8 is preferably 3 or more, more preferably 7 or more, from the viewpoint of improving the feel when applied to the skin, and from the same viewpoint as above, it is preferably 23 or less, more preferably 21 or less, and even more preferably 19 or less.
Specific examples include diisostearyl malate, di-2-ethylhexyl succinate, diisobutyl adipate, di-2-heptylundecyl adipate, di-2-hexyldecyl adipate, di-2-ethylhexyl sebacate, and diisopropyl sebacate.

From the viewpoint of protecting the skin from damage caused by ultraviolet rays, the component (C1) may be an ester-based ultraviolet absorber that has ultraviolet absorbing ability due to its structure.
Examples of the ester-based ultraviolet absorbers include salicylic acid-based ultraviolet absorbers such as homomenthyl salicylate, octyl salicylate, and triethanolamine salicylate; para-aminobenzoic acid-based ultraviolet absorbers such as para-aminobenzoic acid, ethyldihydroxypropylpara-aminobenzoate, glyceryl para-aminobenzoate, octyl dimethylpara-aminobenzoate, amyl dimethylpara-aminobenzoate, and 2-ethylhexyl dimethylpara-aminobenzoate; 2-ethylhexyl para-methoxycinnamate (for example, "Uvinal MC80" manufactured by BASF Japan Ltd.), glyceryl di-para-methoxycinnamate mono-2-ethylhexanoate, methyl 2,5-diisopropylcinnamate, and 2,4,6-tris[4-(2-ethylhexyloxycarbonyl)anilino]-1,3,5-triazine(ethylhexyl Examples of such an ultraviolet absorber include cinnamic acid-based ultraviolet absorbers such as siltriazone (e.g., "Uvinal T150" manufactured by BASF Japan Ltd.), methyl bis(trimethylsiloxy)silylisopentyl trimethoxycinnamate, a mixture of isopropyl p-methoxycinnamate and diisopropyl cinnamate, and diethanolamine p-methoxyhydrocinnamate; octocrylene (e.g., "Parasol 340" manufactured by DSM Nutrition Japan Co., Ltd.); 2-ethylhexyl dimethoxybenzylidene dioxoimidazolidinepropionate (e.g., "Soft Shade DH" manufactured by Ajinomoto Co., Inc.); cinoxate; methyl-O-aminobenzoate; and diethylaminohydroxybenzoylhexyl benzoate (e.g., "Uvinal Aplus" and "Uvinal Aplus GRANULAR" manufactured by BASF Japan Ltd.).

From the viewpoint of improving the adhesion-inhibiting effect and improving the feel when applied to the skin, component (C1) is preferably an ester oil that is liquid at 25°C. An ester oil that is liquid at 25°C is an ester oil having a melting point of 25°C or lower. That is, component (C1) is preferably an ester oil that has fluidity at 25°C under 1 atmosphere. Specifically, it is preferably an ester represented by the general formula (1) or (3), and more preferably one or more selected from isopropyl palmitate, isononyl isononanoate, neopentyl glycol dicaprate, neopentyl glycol di-2-ethylhexanoate, and glyceryl tri-2-ethylhexylate.
When an ester-based ultraviolet absorber is used as component (C1), component (C1) is preferably one or more selected from 2-ethylhexyl paramethoxycinnamate, 2,4,6-tris[4-(2-ethylhexyloxycarbonyl)anilino]-1,3,5-triazine, and diethylaminohydroxybenzoylhexyl benzoate, from the viewpoint of improving the adhesion-inhibiting effect and improving the feel when applied to the skin.

Component (C2) is a non-volatile hydrocarbon oil, and from the viewpoint of providing a good feel when applied to the skin, it is preferably a saturated or unsaturated hydrocarbon having 18 or more carbon atoms.
Specific examples of component (C2) include hydrocarbon oils that are liquid at 25°C, such as squalene, squalane, liquid paraffin, hydrogenated polyisobutene (liquid isoparaffin, heavy liquid isoparaffin), liquid ozokerite, α-olefin oligomer, cycloparaffin, polybutene, and pristane; and hydrocarbon oils that are solid at 25°C, such as petrolatum, ceresin, ozokerite, paraffin wax, microcrystalline wax, and polyethylene wax. Component (C2) can be used singly or in combination of two or more.
Among these, from the viewpoint of providing a good feel when applied to the skin, hydrocarbon oils that have no melting point and are liquid at 25°C are preferred, hydrocarbon oils with a kinematic viscosity at 25°C of 5 ^mm2 /s or more and 100,000 ^mm2 /s or less are more preferred, hydrogenated polyisobutene is even more preferred, and liquid isoparaffin is even more preferred.
The kinematic viscosity of component (C2) at 25°C is more preferably 6 mm ² /s or more from the viewpoint of providing a good feel when applied to the skin, and from the same viewpoint as above, is more preferably 10,000 mm ² /s or less, even more preferably 5,000 mm ² /s or less, even more preferably 1,000 mm ² /s or less, even more preferably 500 mm ² /s or less, even more preferably 300 mm ² /s or less, even more preferably 100 mm ² /s or less, even more preferably 50 mm ² /s or less, and even more preferably 30 mm ² /s or less.
The kinematic viscosity of component (C2) at 25°C can be measured in the same manner as above.
Commercially available products of component (C2) include "Pearleam EX" (liquid isoparaffin) manufactured by NOF Corporation.

[Component (D): Volatile Oil]
The topical preparation may further contain a volatile oil as component (D).
In the present invention, "volatile" means that the amount of evaporation at 25°C in 6 hours, as measured by the above-mentioned method, is more than 20%.

Examples of component (D) include volatile silicone oils and volatile hydrocarbon oils.
The volatile silicone oil used in the present invention is preferably a silicone oil having a kinematic viscosity of less than 5 mm ² /s at 25° C. The kinematic viscosity of component (D) at 25° C. can be measured in the same manner as above.
Volatile silicone oils include linear organopolysiloxanes and cyclic organopolysiloxanes.
Specific examples of linear organopolysiloxanes include octamethyltrisiloxane, decamethyltetrasiloxane, dodecamethylpentasiloxane, and 1,1,1,3,5,5,5-heptamethyl-3-[(trimethylsilyl)oxy]-trisiloxane.
Examples of cyclic organopolysiloxanes include 4- to 6-membered cyclic siloxanes having an alkyl group having 1 to 5 carbon atoms as a substituent, and specific examples include octamethylcyclotetrasiloxane and decamethylcyclopentasiloxane.
Commercially available volatile silicone oils include "KF-96A-1cs" (octamethyltrisiloxane), "KF-96L-1.5cs" (decamethyltetrasiloxane), "KF-96L-2cs" (dodecamethylpentasiloxane), "KF-995" (decamethylcyclopentasiloxane), and "TMF-1.5" (1,1,1,3,5,5,5-heptamethyl-3-[(trimethylsilyl)oxy]-trisiloxane) manufactured by Shin-Etsu Chemical Co., Ltd.; and "SH200C Fluid 1cs" (octamethyltrisiloxane), "SH200C Fluid 1.5cs" (decamethyltetrasiloxane), and "SH200C Fluid 1.5cs" (SH200C Fluid 1.5cs) manufactured by Toray Dow Corning Co., Ltd. 2cs" (dodecamethylpentasiloxane), "SH245 Fluid"(decamethylcyclopentasiloxane); and "TSF405A" (decamethylcyclopentasiloxane) manufactured by Momentive Performance Materials.

Volatile hydrocarbon oils are preferably saturated or unsaturated hydrocarbon oils having 8 to 16 carbon atoms, including, for example, paraffinic hydrocarbon oils such as n-decane, n-undecane, and n-dodecane; isoparaffinic hydrocarbon oils such as isodecane, isododecane, and hydrogenated polyisobutene (light liquid isoparaffin); and cyclic paraffinic hydrocarbon oils such as cyclodecane and cyclododecane.

[Production of topical preparations]
The topical preparation used in the present invention can be produced by appropriately using a known method depending on the dosage form of the topical preparation, for example, by blending component (A), component (B), and, if necessary, the other components described above, and stirring and mixing them using a disperser or the like.
When the topical preparation is a water-in-oil (W/O) type or an oil-in-water (O/W) type, which will be described later, a method can also be used in which an aqueous phase and an oil phase are prepared separately and then the two are mixed together.

(Content of ingredient (A) in topical preparation)
The content of component (A) in the topical preparation is preferably 1% by mass or more, more preferably 2% by mass or more, and even more preferably 3% by mass or more from the viewpoint of improving the adhesion-inhibiting effect, and is preferably 40% by mass or less, more preferably 35% by mass or less, and even more preferably 30% by mass or less from the viewpoint of improving the feel when applied to the skin and from the viewpoint of economy. More specifically, the content of component (A) is preferably 1 to 40% by mass, more preferably 2 to 35% by mass, and even more preferably 3 to 30% by mass from the viewpoint of improving the adhesion-inhibiting effect and from the viewpoint of improving the feel when applied to the skin.

(Total content of component (A1), component (A2), and component (A3) in the topical preparation)
The total content of components (A1), (A2), and (A3) in the topical preparation is preferably 1% by mass or more, more preferably 2% by mass or more, and even more preferably 3% by mass or more, from the viewpoint of improving the adhesion-inhibiting effect, and is preferably 40% by mass or less, more preferably 35% by mass or less, and even more preferably 30% by mass or less, from the viewpoint of improving the feel when applied to the skin and from the viewpoint of economy. More specifically, the total content of components (A1), (A2), and (A3) is preferably 1 to 40% by mass, more preferably 2 to 35% by mass, and even more preferably 3 to 30% by mass, from the viewpoint of improving the adhesion-inhibiting effect and from the viewpoint of improving the feel when applied to the skin.

(Content of ingredient (B) in topical preparation)
The content of component (B) in the topical preparation is preferably 0.05% by mass or more, more preferably 0.1% by mass or more, even more preferably 0.5% by mass or more, and even more preferably 1% by mass or more, from the viewpoint of improving the feel when applied to the skin, and is preferably 15% by mass or less, more preferably 10% by mass or less, even more preferably 8% by mass or less, and even more preferably 6% by mass or less, from the same viewpoint as above and from the viewpoint of improving the adhesion-inhibiting effect.

(Mass ratio [(B)/(A)])
The mass ratio of the content of component (B) to the content of component (A) in the topical preparation [(B)/(A)] (hereinafter referred to as "x1") is 0.85 or less, preferably 0.80 or less, more preferably 0.75 or less, and even more preferably 0.70 or less, from the viewpoint of improving the adhesion-inhibiting effect, and is preferably 0.01 or more, more preferably 0.02 or more, and even more preferably 0.03 or more, from the viewpoint of improving the adhesion-inhibiting effect and the viewpoint of improving the feel when applied to the skin. More specifically, x1 is preferably 0.85 or less and 0.01 or more, more preferably 0.80 or less and 0.01 or more, even more preferably 0.75 or less and 0.02 or more, and even more preferably 0.70 or less and 0.03 or more, from the viewpoint of improving the adhesion-inhibiting effect and the feel when applied to the skin.

(Mass ratio [(B)/[(A1)+(A2)+(A3)]])
When component (A) is one or more selected from component (A1), component (A2), and component (A3), the mass ratio of the content of component (B) to the total content of components (A1), (A2), and (A3) in the topical preparation [(B)/[(A1)+(A2)+(A3)]] (hereinafter referred to as "xI") is, from the viewpoint of improving the adhesion-inhibiting effect, 0.85 or less, preferably 0.80 or less, more preferably 0.75 or less, and even more preferably 0.70 or less, and from the viewpoint of improving the feel when applied to the skin, is preferably 0.01 or more, more preferably 0.02 or more, and even more preferably 0.03 or more. More specifically, from the viewpoint of improving the adhesion suppression effect and improving the feel when applied to the skin, xI is preferably 0.85 or less and 0.01 or more, more preferably 0.80 or less and 0.01 or more, even more preferably 0.75 or less and 0.02 or more, and still more preferably 0.70 or less and 0.03 or more.

When the topical preparation further contains component (C1) (ester oil), the mass ratio β1 (= [[(B) + (C1)]/(A)]) of the total content of component (B) and component (C1) to the content of component (A) in the topical preparation is, from the viewpoint of improving the adhesion-inhibiting effect, preferably 9 or less, more preferably 8 or less, even more preferably 6 or less, still more preferably 4 or less, and still more preferably 3 or less, and from the viewpoint of improving the feel when applied to the skin, is preferably 0.01 or more, more preferably 0.05 or more, and even more preferably 0.1 or more.
From the viewpoint of improving the adhesion-inhibiting effect and improving the feel when applied to the skin, the mass ratio x1 is preferably 0.85 or less and 0.01 or more, and the mass ratio β1 is 9 or less and 0.01 or more, more preferably 0.80 or less and 0.01 or more, and the mass ratio β1 is 8 or less and 0.01 or more, even more preferably 0.75 or less and 0.02 or more, and the mass ratio β1 is 6 or less and 0.05 or more, still more preferably 0.70 or less and 0.03 or more, and the mass ratio β1 is 4 or less and 0.1 or more, and even more preferably 0.70 or less and 0.03 or more, and the mass ratio β1 is 3 or less and 0.1 or more.

When the topical preparation further contains component (C1), the preferred range of the mass ratio βI (=[[(B) + (C1)]/[(A1) + (A2) + (A3)]]) of the total content of component (B) and component (C1) to the total content of component (A1), component (A2), and component (A3) in the topical preparation is the same as the preferred range of the mass ratio β1.
From the viewpoint of improving the adhesion suppression effect and improving the feel when applied to the skin, the mass ratio xI is preferably 0.85 or less and 0.01 or more, and the mass ratio βI is 9 or less and 0.01 or more, more preferably 0.80 or less and 0.01 or more, and the mass ratio βI is 8 or less and 0.01 or more, even more preferably 0.75 or less and 0.02 or more, and the mass ratio βI is 6 or less and 0.05 or more, still more preferably 0.70 or less and 0.03 or more, and the mass ratio βI is 4 or less and 0.1 or more, and even more preferably 0.70 or less and 0.03 or more, and the mass ratio βI is 3 or less and 0.1 or more.

When the topical preparation further contains component (C2) (non-volatile hydrocarbon oil), the mass ratio β2 (= [[(B) + (C2)]/(A)]) of the total content of component (B) and component (C2) to the content of component (A) in the topical preparation is, from the viewpoint of improving the adhesion-inhibiting effect, preferably 3.5 or less, more preferably 3 or less, even more preferably 2.5 or less, and still more preferably 2 or less, and from the viewpoint of improving the feel when applied to the skin, is preferably 0.01 or more, more preferably 0.03 or more, even more preferably 0.05 or more, and still more preferably 0.1 or more.
From the viewpoint of improving the adhesion-inhibiting effect and improving the feel when applied to the skin, the mass ratio x1 is preferably 0.85 or less and 0.01 or more, and the mass ratio β2 is 3.5 or less and 0.01 or more, more preferably the mass ratio x1 is 0.80 or less and 0.01 or more, and the mass ratio β2 is 3 or less and 0.03 or more, even more preferably the mass ratio x1 is 0.75 or less and 0.02 or more, and the mass ratio β2 is 2.5 or less and 0.05 or more, and even more preferably the mass ratio x1 is 0.70 or less and 0.03 or more, and the mass ratio β2 is 2 or less and 0.1 or more.

When the topical preparation further contains component (C2), the preferred numerical range of the mass ratio βII (= [[(B) + (C2)]/[(A1) + (A2) + (A3)]]) of the total content of components (B) and (C2) to the total content of components (A1), (A2), and (A3) in the topical preparation is the same as the preferred numerical range of the mass ratio β2.
From the viewpoint of improving the adhesion suppression effect and improving the feel when applied to the skin, the mass ratio xI is preferably 0.85 or less and 0.01 or more, and the mass ratio βII is 3.5 or less and 0.01 or more, more preferably the mass ratio xI is 0.80 or less and 0.01 or more, and the mass ratio βII is 3 or less and 0.03 or more, even more preferably the mass ratio xI is 0.75 or less and 0.02 or more, and the mass ratio βII is 2.5 or less and 0.05 or more, and even more preferably the mass ratio xI is 0.70 or less and 0.03 or more, and the mass ratio βII is 2 or less and 0.1 or more.

When the topical preparation further contains component (C1) and component (C2), the mass ratio β(1-2) (= [[(B) + (C1) + (C2)]/(A)]) of the total content of component (B), component (C1), and component (C2) to the content of component (A) in the topical preparation is, from the viewpoint of improving the adhesion-inhibiting effect, preferably 9 or less, more preferably 8 or less, even more preferably 6 or less, still more preferably 4 or less, and still more preferably 3 or less, and from the viewpoint of improving the feel when applied to the skin, is preferably 0.01 or more, more preferably 0.05 or more, and even more preferably 0.1 or more.
From the viewpoint of improving the adhesion suppression effect and improving the feel when applied to the skin, the mass ratio x1 is preferably 0.85 or less and 0.01 or more, the mass ratio β2 is 3.5 or less and 0.01 or more, and the mass ratio β(1-2) is 9 or less and 0.01 or more, more preferably the mass ratio x1 is 0.80 or less and 0.01 or more, the mass ratio β2 is 3 or less and 0.03 or more, and the mass ratio β(1-2) is 8 or less and 0.01 or more, and even more preferably the mass ratio x1 is 0.75 or less and 0.02 or more, mass ratio β2 is 2.5 or less and 0.05 or more, and mass ratio β(1-2) is 6 or less and 0.05 or more, even more preferably mass ratio x1 is 0.70 or less and 0.03 or more, mass ratio β2 is 2 or less and 0.1 or more, and mass ratio β(1-2) is 4 or less and 0.1 or more, even more preferably mass ratio x1 is 0.70 or less and 0.03 or more, mass ratio β2 is 2 or less and 0.1 or more, and mass ratio β(1-2) is 3 or less and 0.1 or more.

When the topical preparation further contains component (C1) and component (C2), the preferred range of the mass ratio β(I-II) (=[[(B)+(C1)+(C2)]/[(A1)+(A2)+(A3)]]) of the total content of component (B), component (C1), and component (C2) to the total content of component (A1), component (A2), and component (A3) in the topical preparation is the same as the preferred range of the mass ratio β(1-2).
From the viewpoint of improving the adhesion suppression effect and improving the feeling of use when applied to the skin, the mass ratio xI is preferably 0.85 or less and 0.01 or more, the mass ratio βII is 3.5 or less and 0.01 or more, and the mass ratio β(I-II) is 9 or less and 0.01 or more, more preferably the mass ratio xI is 0.80 or less and 0.01 or more, the mass ratio βII is 3 or less and 0.03 or more, and the mass ratio β(I-II) is 8 or less and 0.01 or more, and even more preferably the mass ratio xI is The mass ratio xI is 0.02 or more and 0.75 or less, the mass ratio βII is 0.05 or more and 2.5 or less, and the mass ratio β(I-II) is 0.05 or more and 6 or less, even more preferably the mass ratio xI is 0.03 or more and 0.70 or less and the mass ratio βII is 0.1 or more and 2 or less, and the mass ratio β(I-II) is 0.1 or more and 4 or less, even more preferably the mass ratio xI is 0.03 or more and 0.70 or less and the mass ratio βII is 0.1 or more and 2 or less, and the mass ratio β(I-II) is 0.1 or more and 3 or less.

(Content of component (C1))
When the topical preparation contains component (C1), the content of component (C1) in the topical preparation is preferably 0.1% by mass or more, more preferably 1% by mass or more, and even more preferably 3% by mass or more, from the viewpoint of improving the feel when applied to the skin, and is preferably 25% by mass or less, more preferably 20% by mass or less, even more preferably 18% by mass or less, and even more preferably 16% by mass or less, from the same viewpoint as above and from the viewpoint of improving the adhesion-inhibiting effect.

(Content of component (C2))
When the topical preparation contains component (C2), the content of component (C2) in the topical preparation is preferably 0.1% by mass or more, more preferably 1% by mass or more, even more preferably 3% by mass or more, and even more preferably 5% by mass or more, from the viewpoint of improving the feel when applied to the skin, and is preferably 25% by mass or less, more preferably 20% by mass or less, even more preferably 18% by mass or less, and even more preferably 16% by mass or less, from the same viewpoint as above and from the viewpoint of improving the adhesion-inhibiting effect.

(Content of component (D))
When the topical preparation contains component (D), the content of component (D) in the topical preparation is, from the viewpoint of improving the adhesion suppression effect, preferably 20% by mass or more, more preferably 25% by mass or more, even more preferably 30% by mass or more, and preferably 97% by mass or less, more preferably 95% by mass or less, even more preferably 93% by mass or less.

The form of the topical agent used in the present invention can be selected appropriately from among oil-based types using a single oil phase as the dispersion medium, water-in-oil types (hereinafter also referred to as "W/O types"), oil-in-water types (hereinafter also referred to as "O/W types"), etc.
In the present invention, the topical preparation can be applied to, for example, the skin or hair. From the viewpoint of adhesion-inhibiting effect, the topical preparation is preferably a cosmetic, more preferably a skin cosmetic.
The dosage form of the external preparation is not particularly limited, and it may be in any dosage form such as liquid, foam, paste, cream, or solid.
When the topical preparation is in the form of an oil, the content and mass ratio of each component are as described above. When the topical preparation is in the form of a W/O or O/W type, the content and mass ratio of each component are as follows:

(Contents and mass ratios of each component in the case of water-in-oil (W/O) type)
When the topical preparation is a W/O type, the content of component (A) in the topical preparation is preferably 1% by mass or more, more preferably 2% by mass or more, even more preferably 3% by mass or more, even more preferably 5% by mass or more, even more preferably 8% by mass or more, and even more preferably 10% by mass or more, from the viewpoint of improving the adhesion-inhibiting effect, and is preferably 40% by mass or less, more preferably 35% by mass or less, and even more preferably 30% by mass or less, from the viewpoint of improving the feel when applied to the skin and from the viewpoint of economy.

When the topical preparation is a W/O type, the total content of components (A1), (A2), and (A3) in the topical preparation is preferably 1% by mass or more, more preferably 2% by mass or more, even more preferably 3% by mass or more, even more preferably 5% by mass or more, even more preferably 8% by mass or more, and even more preferably 10% by mass or more, from the viewpoint of improving the adhesion inhibitory effect; and from the viewpoint of improving the feel when applied to the skin and from the viewpoint of economy, it is preferably 40% by mass or less, more preferably 35% by mass or less, and even more preferably 30% by mass or less.

When the topical preparation is a W/O type, the content of component (B) in the topical preparation is preferably 0.05% by mass or more, more preferably 0.1% by mass or more, even more preferably 0.5% by mass or more, and even more preferably 1% by mass or more, from the viewpoint of improving the adhesion-inhibiting effect and from the viewpoint of preventing stickiness and other sensations during use, and is preferably 15% by mass or less, more preferably 10% by mass or less, even more preferably 8% by mass or less, and even more preferably 6% by mass or less, from the viewpoint of improving the adhesion-inhibiting effect and preventing stickiness and other sensations during use.

When the topical preparation is a W/O type, the mass ratio of the content of component (B) to the content of component (A) in the topical preparation [(B)/(A)] is 0.85 or less, preferably 0.80 or less, more preferably 0.75 or less, and even more preferably 0.70 or less, from the viewpoint of improving the adhesion inhibitory effect, and is preferably 0.01 or more, more preferably 0.02 or more, and even more preferably 0.03 or more, from the viewpoint of improving the feel when applied to the skin.

When the topical preparation is a water-in-oil type and component (A) is one or more selected from component (A1), component (A2), and component (A3), the mass ratio of the content of component (B) to the total content of components (A1), (A2), and (A3) in the topical preparation [(B)/[(A1) + (A2) + (A3)]] is 0.85 or less, preferably 0.80 or less, more preferably 0.75 or less, and even more preferably 0.70 or less. From the viewpoint of improving the feel when applied to the skin, it is preferably 0.01 or more, more preferably 0.02 or more, and even more preferably 0.03 or more.

When the topical preparation is a W/O type and contains component (C1), the content of component (C1) in the topical preparation is preferably 0.1% by mass or more, more preferably 1% by mass or more, and even more preferably 3% by mass or more, from the viewpoint of improving the feel when applied to the skin; and from the same viewpoint as above and from the viewpoint of improving the adhesion-inhibiting effect, it is preferably 25% by mass or less, more preferably 20% by mass or less, even more preferably 18% by mass or less, and even more preferably 16% by mass or less.

When the topical preparation is a W/O type and contains component (C2), the content of component (C2) in the topical preparation is preferably 0.1% by mass or more, more preferably 1% by mass or more, even more preferably 3% by mass or more, even more preferably 5% by mass or more, and even more preferably 8% by mass or more, from the viewpoint of improving the feel when applied to the skin; and from the same viewpoint as above and from the viewpoint of improving the adhesion-inhibiting effect, it is preferably 25% by mass or less, more preferably 20% by mass or less, even more preferably 16% by mass or less, and even more preferably 12% by mass or less.

When the topical preparation is a water-in-oil type and contains component (D), the content of component (D) in the topical preparation is preferably 20% by mass or more, more preferably 25% by mass or more, even more preferably 30% by mass or more, from the viewpoint of improving the adhesion-inhibiting effect, and is preferably 70% by mass or less, more preferably 60% by mass or less, even more preferably 50% by mass or less.

(Contents and mass ratios of each component in the case of oil-in-water (O/W) type)
When the topical preparation is an O/W type, the content of component (A) in the topical preparation is preferably 1% by mass or more, more preferably 2% by mass or more, and even more preferably 3% by mass or more, from the viewpoint of improving the adhesion-inhibiting effect, and is preferably 40% by mass or less, more preferably 35% by mass or less, even more preferably 30% by mass or less, still more preferably 20% by mass or less, and even more preferably 15% by mass or less, from the viewpoint of improving the feel when applied to the skin and from the viewpoint of economy.

When the topical preparation is an O/W type, the total content of components (A1), (A2), and (A3) in the topical preparation is preferably 1% by mass or more, more preferably 2% by mass or more, and even more preferably 3% by mass or more, from the viewpoint of improving the adhesion inhibitory effect; and from the viewpoint of improving the feel when applied to the skin and from the viewpoint of economy, it is preferably 40% by mass or less, more preferably 35% by mass or less, even more preferably 30% by mass or less, even more preferably 20% by mass or less, and even more preferably 15% by mass or less.

When the topical preparation is an O/W type, the content of component (B) in the topical preparation is preferably 0.05% by mass or more, more preferably 0.1% by mass or more, even more preferably 0.5% by mass or more, and even more preferably 1% by mass or more, from the viewpoint of improving the adhesion-inhibiting effect and from the viewpoint of preventing stickiness and other sensations during use, and is preferably 15% by mass or less, more preferably 10% by mass or less, even more preferably 8% by mass or less, and even more preferably 6% by mass or less, from the viewpoint of improving the adhesion-inhibiting effect and preventing stickiness and other sensations during use.

When the topical preparation is an O/W type, the mass ratio of the content of component (B) to the content of component (A) in the topical preparation [(B)/(A)] is 0.85 or less, preferably 0.80 or less, more preferably 0.75 or less, and even more preferably 0.70 or less, from the viewpoint of improving the adhesion inhibitory effect, and is preferably 0.01 or more, more preferably 0.03 or more, even more preferably 0.05 or more, and even more preferably 0.10 or more, from the viewpoint of improving the feel when applied to the skin.

When the topical preparation is an O/W type and component (A) is one or more selected from component (A1), component (A2), and component (A3), the mass ratio of the content of component (B) to the total content of components (A1), (A2), and (A3) in the topical preparation [(B)/[(A1) + (A2) + (A3)]] is 0.85 or less, preferably 0.80 or less, more preferably 0.75 or less, and even more preferably 0.70 or less, from the viewpoint of improving the adhesion-inhibiting effect. Also, from the viewpoint of improving the feel when applied to the skin, it is preferably 0.01 or more, more preferably 0.03 or more, even more preferably 0.05 or more, and even more preferably 0.10 or more.

When the topical preparation is an O/W type and contains component (C1), the content of component (C1) in the topical preparation is preferably 0.1% by mass or more, more preferably 1% by mass or more, even more preferably 3% by mass or more, even more preferably 5% by mass or more, even more preferably 8% by mass or more, and even more preferably 10% by mass or more, from the viewpoint of improving the feel when applied to the skin; and from the same viewpoint as above and from the viewpoint of improving the adhesion-inhibiting effect, it is preferably 25% by mass or less, more preferably 20% by mass or less, even more preferably 18% by mass or less, and even more preferably 16% by mass or less.

When the topical preparation is an O/W type and contains component (C2), the content of component (C2) in the topical preparation is preferably 0.1% by mass or more, more preferably 1% by mass or more, even more preferably 3% by mass or more, even more preferably 5% by mass or more, even more preferably 8% by mass or more, and even more preferably 10% by mass or more, from the viewpoints of improving the feel when applied to the skin, and is preferably 25% by mass or less, more preferably 20% by mass or less, and even more preferably 16% by mass or less, from the same viewpoint as above and from the viewpoint of improving the adhesion-inhibiting effect.

When the topical preparation is an oil-in-water type and contains component (D), the content of component (D) in the topical preparation is preferably 0.01% by mass or more, more preferably 0.03% by mass or more, even more preferably 0.05% by mass or more, from the viewpoint of improving the adhesion-inhibiting effect, and is preferably 7% by mass or less, more preferably 5% by mass or less, even more preferably 3% by mass or less.

[Coating method]
In the present invention, the topical preparation can be applied to the skin by a known method depending on the form or purpose of use of the topical preparation. Here, "applying to the skin" includes not only directly applying the topical preparation to the skin surface with the hands, etc., but also attaching the topical preparation to the skin surface by spraying, etc. The topical preparations in the form of liquid, foam, paste, cream, or solid can usually be applied directly by application, spraying, etc.

(Amount of component (A) applied)
The amount of component (A) applied to the skin surface is preferably 0.03 mg/cm2 or ^more , more preferably 0.04 mg/cm2 or more, even more preferably 0.05 mg/cm2 or ^more , and still more preferably 0.07 mg/ ^cm2 or more, from the viewpoint of improving the adhesion-inhibiting effect, and is preferably 0.8 mg/cm2 ^{or less} , more preferably 0.7 mg/cm2 or less, and even more preferably 0.6 mg/ ^{cm2 or less} , from the viewpoint of improving the feel when applied to the skin and from the viewpoint of economy. More specifically, the amount of component (A) applied to the skin surface is preferably 0.03 to 0.8 mg/cm 2, more preferably 0.04 to 0.8 mg/cm ² , even more preferably 0.05 to 0.8 mg/cm 2, still more preferably 0.07 to 0.8 mg/cm ² , even more preferably 0.07 to 0.7 mg/cm ² , and even more preferably 0.07 to 0.6 mg/cm ² , from the viewpoints of improving the adhesion-inhibiting ^effect , improving the feel when applied to the skin, and ^economy .

When component (A) is one or more selected from component (A1), component (A2), and component (A1), the total amount of component (A1), component (A2), and component (A3) applied to the skin surface is, from the viewpoint of improving the adhesion-inhibiting effect, preferably at least 0.03 mg/ ^cm2 , more preferably at least 0.04 mg/ ^cm2 , even more preferably at least 0.05 mg/ ^cm2 , and still more preferably at least 0.07 mg/ ^cm2 , and from the viewpoint of improving the feel when applied to the skin and from the viewpoint of economy, preferably at most 0.8 mg/ ^cm2 , more preferably at most 0.7 mg/ ^cm2 , and even more preferably at most 0.6 mg/ ^cm2 . More specifically, the total amount of component (A1), component (A2), and component (A3) applied to the skin surface is preferably 0.03 to 0.8 mg/cm ² , more preferably 0.04 to 0.8 mg/cm 2 , even more preferably 0.05 to 0.8 mg/cm ² , still more preferably 0.07 to 0.8 mg/cm 2 , even more preferably 0.07 to 0.7 mg/cm ² , and still more preferably 0.07 to 0.6 mg/cm ² , from the viewpoints of improving the adhesion-inhibiting effect, improving the feel when applied to ^the skin, ^and economy.

When the topical preparation is a W/O type, the amount of component (A) applied to the skin surface is, from the viewpoint of improving the adhesion-inhibiting effect, preferably 0.03 mg/ ^cm2 or more, more preferably 0.04 mg/ ^cm2 or more, even more preferably 0.05 mg/ ^cm2 or more, still more preferably 0.07 mg/ ^cm2 or more, still more preferably 0.10 mg/cm2 or ^more , and still more preferably 0.20 mg/cm2 or ^more , and from the viewpoint of improving the feel when applied to the skin and from the viewpoint of economy, is preferably 0.8 mg/cm2 or ^less , more preferably 0.7 mg/cm2 or ^less , and even more preferably 0.6 mg/cm2 ^{or less} . More specifically, the amount of component (A) applied to the skin surface is preferably 0.03 to 0.8 mg/cm 2 , more preferably 0.04 to 0.8 mg/cm ² , even more preferably 0.05 to 0.8 mg/cm 2 , still more preferably 0.07 to 0.8 mg/cm ² , even more preferably 0.10 to 0.8 mg/cm ² , still more preferably 0.20 to 0.7 mg/cm ² , and still more preferably 0.20 to 0.6 mg/cm ² , from the viewpoints of improving the adhesion-inhibiting effect, improving the feel when applied to ^the skin, ^and economy.

When the topical preparation is a water-in-oil type and component (A) is one or more selected from component (A1), component (A2), and component (A3), the total amount of component (A1), component (A2), and component (A3) applied to the skin surface is, from the viewpoint of improving the adhesion-inhibiting effect, preferably at ^least 0.03 mg/cm2, more preferably at least 0.04 mg/ ^cm2 , even more preferably at least 0.05 mg/ ^cm2 , still more preferably at least 0.07 mg/ ^cm2 , still more preferably at least 0.10 mg/ ^cm2 , and still more preferably at least 0.20 mg/ ^cm2 ; and, from the viewpoint of improving the feel when applied to the skin and from the viewpoint of economy, is preferably at most 0.8 mg/ ^cm2 , more preferably at most 0.7 mg/ ^cm2 , and even more preferably at most 0.6 mg/ ^cm2 . The specific range of the total amount of component (A1), component (A2) and component (A3) to be applied to the skin surface is preferably 0.03 to 0.8 mg/cm ² , more preferably 0.04 to 0.8 mg/cm 2 , even more preferably 0.05 to 0.8 mg/cm ^{2 , still more preferably 0.07 to 0.8 mg/cm 2} , still more preferably 0.10 to 0.8 mg/cm ² , still more preferably 0.20 to 0.7 mg/cm ² , and still more preferably 0.20 to 0.6 mg/cm ² , from the viewpoints of improving the adhesion-inhibiting effect, improving the feel when applied to the ^skin , and ^economy .

When the topical preparation is an O/W type, the amount of component (A) applied to the skin surface is preferably 0.03 mg/cm2 or ^more , more preferably 0.04 mg/cm2 or more, even more preferably 0.05 mg/ ^cm2 or ^more , and still more preferably 0.07 mg/cm2 or more, from the viewpoint of improving the adhesion-inhibiting effect, and is preferably 0.8 mg/cm2 or ^less , more preferably 0.7 mg/ ^{cm2 or} less, even more preferably 0.6 mg/cm2 or less, and still more preferably 0.3 mg/cm2 ^{or less} , from the viewpoint of improving the feel when applied to the skin and from the viewpoint of economy. More specifically, the amount of component (A) applied to the skin surface is preferably 0.03 to 0.8 mg/cm 2 , more preferably 0.04 to 0.8 mg/cm ² , even more preferably 0.05 to 0.8 mg/cm 2 , still more preferably 0.07 to 0.8 mg/cm ² , even more preferably 0.07 to 0.7 mg/cm ² , still more preferably 0.07 to 0.6 mg/cm ² , and still more preferably 0.07 to 0.3 mg/cm ² , from the viewpoints of improving the adhesion-inhibiting effect, improving the feel when applied to ^the skin, ^and economy.

When the topical preparation is an O/W type and component (A) is one or more selected from component (A1), component (A2), and component (A3), the total amount of component (A1), component (A2), and component (A3) applied to the skin surface is, from the viewpoint of improving the adhesion-inhibiting effect, preferably 0.03 mg/cm2 or ^more , more preferably 0.04 mg/cm2 or ^more , even more preferably 0.05 mg/ ^cm2 or more, and still more preferably 0.07 mg/cm2 or ^more , and from the viewpoint of improving the feel when applied to the skin and from the viewpoint of economy, preferably 0.8 mg/cm2 or ^less , more preferably 0.7 mg/cm2 or ^less , even more preferably 0.6 mg/cm2 or ^less , and still more preferably 0.3 mg/cm2 or ^less . More specifically, the total amount of component (A1), component (A2), and component (A3) applied to the skin surface is preferably 0.03 to 0.8 mg/cm ² , more preferably 0.04 to 0.8 mg/cm 2 , even more preferably 0.05 to 0.8 mg/cm 2 , still more preferably 0.07 to 0.8 mg/cm ² , even more preferably 0.07 to 0.7 mg/cm ² , still more preferably 0.07 to 0.6 mg/cm ² , and still more preferably 0.07 to 0.3 mg/ ^{cm 2 ,} from the viewpoints of improving the adhesion-inhibiting effect, improving the feel when applied to the skin, and ^economy .

In addition to the above-described embodiment, the present invention also discloses the following embodiments.
<1> A method for suppressing adhesion of atmospheric hazardous substances by applying an external preparation to the skin to suppress adhesion of atmospheric hazardous substances to the skin,
The topical preparation contains one or more selected from the following components (A1), (A2), and (A3), and component (B), and the mass ratio of the content of component (B) to the total content of components (A1), (A2), and (A3) in the topical preparation [(B)/[(A1)+(A2)+(A3)]] is 0.85 or less and 0.01 or more.
Component (A1): one or more selected from fatty acid-treated titanium oxide and zinc oxide, having an average primary particle diameter d _A of 5 nm or more and 80 nm or less. Component (A2): one or more selected from alkylalkoxysilane-treated titanium oxide and zinc oxide, having an average primary particle diameter d _A of 5 nm or more and 80 nm or less. Component (A3): one or more selected from silicone-treated titanium oxide and zinc oxide, having an average primary particle diameter d _A of 5 nm or more and 80 nm or less. Component (B): non-volatile silicone oil.

<2> A method for suppressing adhesion of atmospheric hazardous substances, comprising applying an external preparation to the skin to suppress adhesion of atmospheric hazardous substances to the skin,
The topical preparation contains one or more selected from the following components (A1), (A2), and (A3), and component (B), and the mass ratio of the content of component (B) to the total content of components (A1), (A2), and (A3) in the topical preparation [(B)/[(A1)+(A2)+(A3)]] is 0.85 or less and 0.01 or more.
Component (A1): one or more selected from fatty acid-treated titanium oxide and zinc oxide, having an average primary particle diameter d _A of 5 nm or more and 50 nm or less. Component (A2): one or more selected from alkylalkoxysilane-treated titanium oxide and zinc oxide, having an average primary particle diameter d _A of 5 nm or more and 50 nm or less. Component (A3): one or more selected from silicone-treated titanium oxide and zinc oxide, having an average primary particle diameter d _A of 5 nm or more and 50 nm or less. Component (B): non-volatile silicone oil.

<3> The method for suppressing adhesion of atmospheric hazardous substances according to <1> or <2>, wherein the mass ratio [(B)/[(A1)+(A2)+(A3)]] is 0.75 or less and 0.02 or more.
<4> The method for suppressing adhesion of atmospheric hazardous substances according to <1> or <2>, wherein the mass ratio [(B)/[(A1)+(A2)+(A3)]] is 0.70 or less and 0.03 or more.

<5> The method for suppressing adhesion of atmospheric hazardous substances according to any one of <1> to <4>, wherein the total amount of component (A1), component (A2), and component (A3) applied to the skin is 0.03 mg/ ^cm2 or more and 0.8 mg/ ^cm2 or less.
<6> The method for suppressing adhesion of atmospheric hazardous substances according to any one of <1> to <4>, wherein the total amount of component (A1), component (A2), and component (A3) applied to the skin is 0.05 mg/ ^cm2 or more and 0.8 mg/ ^cm2 or less.
<7> The method for suppressing adhesion of atmospheric hazardous substances according to any one of <1> to <4>, wherein the total amount of component (A1), component (A2), and component (A3) applied to the skin is 0.07 mg/cm2 or ^more and 0.7 mg/ ^cm2 or less.

<8> The method for suppressing adhesion of atmospheric hazardous substances according to any one of <1> to <7>, wherein the total content of the component (A1), the component (A2), and the component (A3) in the topical preparation is 1% by mass or more and 40% by mass or less.
<9> The method for suppressing adhesion of atmospheric hazardous substances according to any one of <1> to <7>, wherein the total content of the component (A1), the component (A2), and the component (A3) in the topical preparation is 2% by mass or more and 35% by mass or less.
<10> The method for suppressing adhesion of atmospheric hazardous substances according to any one of <1> to <7>, wherein the total content of the component (A1), the component (A2), and the component (A3) in the topical preparation is 3% by mass or more and 30% by mass or less.

<11> A method for suppressing adhesion of atmospheric hazardous substances, comprising applying an external preparation to the skin to suppress adhesion of atmospheric hazardous substances to the skin,
The topical preparation contains one or more selected from the following components (A1), (A2), and (A3), and component (B), wherein the mass ratio of the content of component (B) to the total content of components (A1), (A2), and (A3) in the topical preparation [(B)/[(A1) + (A2) + (A3)]] is 0.75 or less and 0.02 or more, and the total amount of components (A1), (A2), and (A3) applied to the skin is 0.03 mg/cm2 or ^more and 0.8 mg/ ^cm2 or less.
Component (A1): one or more selected from fatty acid-treated titanium oxide and zinc oxide, having an average primary particle diameter d _A of 5 nm or more and 80 nm or less. Component (A2): one or more selected from alkylalkoxysilane-treated titanium oxide and zinc oxide, having an average primary particle diameter d _A of 5 nm or more and 80 nm or less. Component (A3): one or more selected from silicone-treated titanium oxide and zinc oxide, having an average primary particle diameter d _A of 5 nm or more and 80 nm or less. Component (B): non-volatile silicone oil.

<12> A method for suppressing adhesion of atmospheric hazardous substances, comprising applying an external preparation to the skin to suppress adhesion of atmospheric hazardous substances to the skin,
The topical preparation contains one or more selected from the following components (A1), (A2), and (A3), and component (B), wherein the mass ratio of the content of component (B) to the total content of components (A1), (A2), and (A3) in the topical preparation [(B)/[(A1) + (A2) + (A3)]] is 0.03 or more and 0.70 or less, and the total amount of components (A1), (A2), and (A3) applied to the skin is 0.03 mg/cm2 or ^more and 0.8 mg/ ^cm2 or less.
Component (A1): one or more selected from fatty acid-treated titanium oxide and zinc oxide, having an average primary particle diameter d _A of 5 nm or more and 50 nm or less. Component (A2): one or more selected from alkylalkoxysilane-treated titanium oxide and zinc oxide, having an average primary particle diameter d _A of 5 nm or more and 50 nm or less. Component (A3): one or more selected from silicone-treated titanium oxide and zinc oxide, having an average primary particle diameter d _A of 5 nm or more and 50 nm or less. Component (B): non-volatile silicone oil.

<13> A method for suppressing adhesion of atmospheric hazardous substances, comprising applying an external preparation to the skin to suppress adhesion of atmospheric hazardous substances to the skin,
The topical preparation contains one or more selected from the following components (A1), (A2), and (A3), and component (B), wherein the mass ratio of the content of component (B) to the total content of components (A1), (A2), and (A3) in the topical preparation [(B)/[(A1) + (A2) + (A3)]] is 0.75 or less and 0.02 or more, and the total content of components (A1), (A2), and (A3) in the topical preparation is 1% by mass or more and 40% by mass or less.
Component (A1): one or more selected from fatty acid-treated titanium oxide and zinc oxide, having an average primary particle diameter d _A of 5 nm or more and 80 nm or less. Component (A2): one or more selected from alkylalkoxysilane-treated titanium oxide and zinc oxide, having an average primary particle diameter d _A of 5 nm or more and 80 nm or less. Component (A3): one or more selected from silicone-treated titanium oxide and zinc oxide, having an average primary particle diameter d _A of 5 nm or more and 80 nm or less. Component (B): non-volatile silicone oil.

<14> A method for suppressing adhesion of atmospheric hazardous substances, comprising applying an external preparation to the skin to suppress adhesion of atmospheric hazardous substances to the skin,
The topical preparation contains one or more selected from the following components (A1), (A2), and (A3), and component (B), wherein the mass ratio of the content of component (B) to the total content of components (A1), (A2), and (A3) in the topical preparation [(B)/[(A1) + (A2) + (A3)]] is 0.70 or less and 0.03 or more, and the total content of components (A1), (A2), and (A3) in the topical preparation is 1% by mass or more and 40% by mass or less.
Component (A1): one or more selected from fatty acid-treated titanium oxide and zinc oxide, having an average primary particle diameter d _A of 5 nm or more and 50 nm or less. Component (A2): one or more selected from alkylalkoxysilane-treated titanium oxide and zinc oxide, having an average primary particle diameter d _A of 5 nm or more and 50 nm or less. Component (A3): one or more selected from silicone-treated titanium oxide and zinc oxide, having an average primary particle diameter d _A of 5 nm or more and 50 nm or less. Component (B): non-volatile silicone oil.

<15> A method for suppressing adhesion of atmospheric hazardous substances, comprising applying an external preparation to the skin to suppress adhesion of atmospheric hazardous substances to the skin,
a mass ratio of the content of component (B) to the total content of components (A1), (A2), and (A3) in the topical preparation [(B)/[(A1)+(A2)+(A3)]] is 0.70 or less and 0.03 or more; a mass ratio of the content of the total content of components (B) and (C1) to the total content of components (A1), (A2), and (A3) in the topical preparation [[(B)+(C1)]/[(A1)+(A2)+(A3)]] is 4 or less and 0.1 or more; and the total content of components (A1), (A2), and (A3) in the topical preparation is 1% by mass or more and 40% by mass or less.
Component (A1): One or more selected from fatty acid-treated titanium oxide and zinc oxide, having an average primary particle diameter d _A of 5 nm or more and 50 nm or less. Component (A2): One or more selected from alkylalkoxysilane-treated titanium oxide and zinc oxide, having an average primary particle diameter d _A of 5 nm or more and 50 nm or less. Component (A3): One or more selected from silicone-treated titanium oxide and zinc oxide, having an average primary particle diameter d _A of 5 nm or more and 50 nm or less. Component (B): Non-volatile silicone oil. Component (C1): Ester oil.

<16> A method for suppressing adhesion of atmospheric hazardous substances, comprising applying an external preparation to the skin to suppress adhesion of atmospheric hazardous substances to the skin,
a mass ratio of the content of component (B) to the total content of components (A1), (A2), and (A3) in the topical preparation [(B)/[(A1)+(A2)+(A3)]] is 0.70 or less and 0.03 or more; a mass ratio of the content of the total content of components (B) and (C2) to the total content of components (A1), (A2), and (A3) in the topical preparation [[(B)+(C2)]/[(A1)+(A2)+(A3)]] is 2 or less and 0.1 or more; and the total content of components (A1), (A2), and (A3) in the topical preparation is 1% by mass or more and 40% by mass or less.
Component (A1): One or more selected from fatty acid-treated titanium oxide and zinc oxide, having an average primary particle diameter d _A of 5 nm or more and 50 nm or less. Component (A2): One or more selected from alkylalkoxysilane-treated titanium oxide and zinc oxide, having an average primary particle diameter d _A of 5 nm or more and 50 nm or less. Component (A3): One or more selected from silicone-treated titanium oxide and zinc oxide, having an average primary particle diameter d _A of 5 nm or more and 50 nm or less. Component (B): Non-volatile silicone oil. Component (C2): Non-volatile hydrocarbon oil.

<17> A method for suppressing adhesion of atmospheric hazardous substances, comprising applying an external preparation to the skin to suppress adhesion of atmospheric hazardous substances to the skin,
The topical preparation contains one or more selected from the following components (A1), (A2), and (A3), and components (B), (C1), and (C2), and the mass ratio of the content of component (B) to the total content of components (A1), (A2), and (A3) in the topical preparation [(B)/[(A1)+(A2)+(A3)]] is 0.70 or less and 0.03 or more, and the mass ratio of the total content of components (B) and (C2) to the total content of components (A1), (A2), and (A3) in the topical preparation [[( a mass ratio [[(B)+(C1)+(C2)]/[(A1)+(A2)+(A3)]] of the total content of components (B), (C1) and (C2) to the total content of components (A1), (A2) and (A3) in the topical preparation is 4 or less and 0.1 or more, and the total content of components (A1), (A2) and (A3) in the topical preparation is 1% by mass or more and 40% by mass or less.
Component (A1): One or more selected from fatty acid-treated titanium oxide and zinc oxide, having an average primary particle diameter d _A of 5 nm or more and 50 nm or less. Component (A2): One or more selected from alkylalkoxysilane-treated titanium oxide and zinc oxide, having an average primary particle diameter d _A of 5 nm or more and 50 nm or less. Component (A3): One or more selected from silicone-treated titanium oxide and zinc oxide, having an average primary particle diameter d _A of 5 nm or more and 50 nm or less. Component (B): Non-volatile silicone oil. Component (C1): Ester oil. Component (C2): Non-volatile hydrocarbon oil.

<18> The method for suppressing adhesion of air hazardous substances according to any one of <11> to <17>, wherein the topical preparation is a water-in-oil type, and the total content of component (A1), component (A2), and component (A3) in the topical preparation is 10% by mass or more and 40% by mass or less.
<19> The method for suppressing adhesion of air hazardous substances according to any one of <11> to <17>, wherein the topical preparation is an oil-in-water type, and the total content of component (A1), component (A2), and component (A3) in the topical preparation is 1% by mass or more and 15% by mass or less.
<20> The method for suppressing adhesion of atmospheric harmful substances according to any one of <11> to <19>, wherein the content of the component (B) in the topical preparation is 1% by mass or more and 6% by mass or less.
<21> The method for suppressing adhesion of atmospheric hazardous substances according to any one of <11> to <20>, wherein the total amount of component (A1), component (A2), and component (A3) applied to the skin is 0.05 mg/ ^cm2 or more and 0.8 mg/ ^cm2 or less.
<22> The method for suppressing adhesion of atmospheric hazardous substances according to any one of <11> to <20>, wherein the total amount of component (A1), component (A2), and component (A3) applied to the skin is 0.07 mg/cm2 or ^more and 0.7 mg/ ^cm2 or less.

In the following examples and comparative examples, "parts" and "%" are "parts by mass" and "% by mass" unless otherwise specified.

(Average primary particle diameter d _A of component (A))
When component (A) has a shape other than a plate shape, a dispersion of component (A) prepared in advance was placed on the sample stage of a transmission electron microscope (TEM) (manufactured by JEOL Ltd., trade name "JEM1400Plus") and air-dried. The maximum minor diameters of 300 primary particles in an image observed with the TEM at a magnification of 50,000 times were measured, and the number average value thereof was defined as the average primary particle diameter d _A. Here, the maximum minor diameter means the minor diameter having the longest length among the minor diameters perpendicular to the major diameter.
When component (A) was plate-like, the thicknesses of 300 primary particles in an image observed under the same observation magnification conditions as above were measured, and the number average value was taken as the average primary particle diameter _dA .
The dispersion of component (A) was prepared by adding 95 g of ethanol as a solvent to 5 g of component (A) and subjecting the mixture to ultrasonic dispersion.

(Kinematic viscosity at 25°C)
The kinematic viscosity at 25°C was measured using an Ubbelohde viscometer in accordance with ASTM D 445-46T or JIS Z 8803.

In the examples and comparative examples, commercially available products of component (A) shown in Table 1 below were used.

Examples 1 to 12, Comparative Examples 1 to 9, Reference Examples 1 to 4
Component (A) or component (A'), component (B) and component (D) were stirred and mixed at room temperature according to the compositions shown in Tables 2 to 6 to obtain the topical preparations of Examples 1 to 12 and Comparative Examples 1 to 9.
Dimethylpolysiloxane (manufactured by Shin-Etsu Chemical Co., Ltd., "KF-96L-6cs", kinematic viscosity at 25°C: 6 mm ² /s) was used as component (B), and dodecamethylpentasiloxane (manufactured by Shin-Etsu Chemical Co., Ltd., trade name "KF-96L-2cs", kinematic viscosity at 25°C: 2 mm ² /s) was used as component (D).
Furthermore, as component (A'), a methylsiloxane network polymer ("Tospearl 145A" manufactured by Momentive Performance Materials Japan, LLC (spherical silicone microparticles, average particle size: 4.5 μm (catalog value))) and silica particles ("Sunsphere NP-30" manufactured by AGC Si-Tech Co., Ltd. (average particle size: 4 μm (catalog value))) were used.
In Reference Examples 1 to 4, component (B) was not used, and component (A) and component (D) were stirred and mixed to form the compositions shown in Tables 2 to 5, and used as topical preparations.
The effect of inhibiting the adhesion of air hazardous substances using the obtained topical preparations was evaluated by the following method, and the results are shown in Tables 2 to 6.

<Method for evaluating the effect of suppressing adhesion of atmospheric hazardous substances>
The topical preparation obtained above was applied to white artificial leather (trade name "Laforet S2923", manufactured by Okamoto Shinwa Co., Ltd.) as a skin substitute so that the amount of component (A) or component (A') applied was 0.12 mg/ ^cm² , and the application was allowed to dry overnight at room temperature.
The surface of the artificial leather to which the topical agent was applied was exposed to an environment in which the atmospheric hazardous substance for evaluation was blown, and the L ^* a ^* b ^* values were measured using a colorimeter, and the color difference ΔE before and after exposure was measured using the following method.
[Measurement of color difference ΔE]
Using a colorimeter (product name "CM-2002", manufactured by Konica Minolta, Inc.), the L ₁ ^* , a ₁ ^* and b ₁ ^* values of the surface of the artificial leather to which the topical agent was applied before exposure to the atmospheric hazardous substances for evaluation were measured.
Separately, a blower (product name "Silky Wind 9ZF002RH02", size: 129 × 106 × 83 mm, manufactured by Rhythm Watch Co., Ltd.) and a mesh sieve (Test sieves JIS Z 8801, frame dimensions: φ100 × 45H, mesh size: 106 μm, manufactured by Tokyo Screen Co., Ltd.) were fixed inside a glove bag (product number "3-118-01", manufactured by AS ONE Corporation). The mesh sieve was installed at a height of 17 cm.
An artificial leather (5 cm x 4 cm) coated with the test sample topical agent was attached to a support so that the lower end of the artificial leather was at a height of 11 cm. The distance between the coated surface of the artificial leather on the support and the air blower was 15 cm, and the coated surface of the artificial leather was perpendicular to the direction of airflow from the air blower, as shown in Figure 1, and the center height of the air blower blades was the same as the center height of the artificial leather.
The temperature inside the glove bag was set to 25°C and the relative humidity to 57% RH, and 50 mg of graphite powder (trade name "J-CPB", average particle size: 5.5 μm, manufactured by Nippon Graphite Industries Co., Ltd.) was sorted as an air hazardous substance to be evaluated using a mesh sieve de-clogging brush (trade name "JNB-5", brush diameter 53 μm, manufactured by Tokyo Screen Co., Ltd.) and dropped in front of the outlet of a blower with the air blowing scale set to 1 for 1 minute, exposing the surface of the artificial leather to which the topical agent had been applied to the air-blowing environment of the air hazardous substance to be evaluated.
Next, the L ₂ ^* , a ₂ ^* and b ₂ ^* values of the exposed artificial leather surface were measured using the above colorimeter, and the color difference ΔE value was calculated using the following formula (I).
ΔE = [(L ₁ ^* - L ₂ ^* ) ² + (a ₁ ^* - a ₂ ^* ) ² + (b ₁ ^* - b ₂ ^* ) ² ] ^0.5 (I)
The above operation was carried out three times for each test sample, and the average value of the color difference ΔE of the artificial leather to which the topical agent of the test sample was applied was taken as ΔEt. Furthermore, the same operation as above was carried out three times for the artificial leather to which the topical agent was not applied as a standard sample, and the average value of the color difference ΔE was taken as ΔEs, and the adhesion inhibition rate was calculated using the following formula (II). The higher the adhesion inhibition rate, the better the effect of inhibiting the adhesion of atmospheric harmful substances.
Air hazardous substance adhesion inhibition rate (%) = 100 × (ΔEs - ΔEt) / ΔEs (II)

From Tables 2 to 6, it can be seen that Examples 1 to 12 have a higher adhesion suppression effect than Comparative Examples 1 to 9 by applying a topical agent containing component (A) and component (B) in which the mass ratio of component (B) to component (A) [(B)/(A)] is 0.85 or less.
Furthermore, compared to Reference Examples 1 to 4, the topical preparations of Examples 1 to 12 contain component (B), and therefore have a good feel (touch) when used.

Examples 13 to 19
The topical preparations shown in the following Formulation Examples 1 to 7 were prepared and evaluated in the same manner as described above for the inhibitory effect on the adhesion of atmospheric hazardous substances, except that 2 mg/ ^cm2 of each topical preparation was applied to white artificial leather. The results are shown in Table 7.
The notations in the prescription examples are as follows:
*1: Sakai Chemical Industry Co., Ltd. "STR-100C-LF"
*2: MICRO ZINC OXIDE MZ-504R3M manufactured by Teika Corporation
* 3: "Estemol N-01" manufactured by Nisshin Oillio Group Co., Ltd.
*4: NOF Corporation "Pearleam EX"
* 5: "Nikkol Squalane" manufactured by Nippon Surfactant Industries Co., Ltd.
*6: "KF-96A-10CS" manufactured by Shin-Etsu Chemical Co., Ltd.
*7: "Sphingolipid E" manufactured by Kao Corporation
*8: "KF-6015" manufactured by Shin-Etsu Chemical Co., Ltd.
*9: "KF-96L-2CS" manufactured by Shin-Etsu Chemical Co., Ltd.
*10: "Tospearl 145A" manufactured by Momentive Performance Materials Japan LLC
*11: "SI-Talc JA-46R" manufactured by Miyoshi Kasei Co., Ltd.
*12: Kao Corporation "Excepearl TGO"
*13: "KF-96A-6CS" manufactured by Shin-Etsu Chemical Co., Ltd.
* 14: Sakai Chemical Industry Co., Ltd. "FINEX-30-OTS (K)"
*15: "Ubinar MC80" manufactured by BASF Japan Ltd.
*16: "TINOSORB S" manufactured by BASF Japan Ltd.
*17: Kao Corporation "Excepar IPP"
*18: "Silicone TSF405A" manufactured by Momentive Performance Materials Japan LLC
*19: Ishihara Sangyo Kaisha "MPT-171"
*20: "Cetyl Alcohol NX" manufactured by Kokyu Alcohol Kogyo Co., Ltd.
*21: "Montex A" manufactured by Miyoshi Oil Co., Ltd.
*22: Kao Corporation "Emulgen 1620G"
*23: Lubrizol Advanced Materials, Inc. Manufactured by "PEMULENTR-1"
*24: Lubrizol Advanced Materials, Inc. Manufactured by "PEMULENTR-2"
* 25: Sakai Chemical Industry Co., Ltd. "STR-100W-OTS"
*26: "Ubinar T150" manufactured by BASF Japan Ltd.
*27: Kao Corporation "Leodor TW-S120V"
*28: NOF Corporation "Pearleam 4"
*29: Kao Corporation "Leodor SP-S10V"
*30: "Salacos 99" manufactured by Nisshin Oillio Group Co., Ltd.

Formulation Example 1 (W/O type external preparation, mass ratio [(C1)/(A)] = 0.31, mass ratio [(C2)/(A)] = 0.35, mass ratio [(B)/(A)] = 0.04)
(Ingredients (amount))
Stearic acid-treated titanium oxide (component (A1)) * 1 7 parts Silicone-treated zinc oxide (component (A3)) * 2 19 parts Neopentyl glycol dicaprate (component (C1)) * 3 3 parts Glyceryl tri-2-ethylhexanoate (component (C1)) * 12 5 parts Liquid isoparaffin (component (C2)) * 4 5 parts Squalane (component (C2)) * 5 4 parts Dimethylpolysiloxane (25 ° C. kinematic viscosity: 10 mm ² /s) (component (B)) * 6 1 part N- (hexadecyloxyhydroxypropyl) -N- hydroxyethylhexadecanamide * 7 1.5 parts Polyoxyethylene / methylpolysiloxane copolymer (HLB: 4.5) * 8 1.4 parts Dodecamethylpentasiloxane (25 ° C. kinematic viscosity: 2 mm ² /s) (component (D)) * 9 35.1 parts Methylsiloxane network polymer *10 3 parts Silicone-coated talc *11 1.9 parts Glycerin (86%) 1 part
Purified water remainder
Total 100 copies

Formulation Example 2 (W/O type external preparation) (mass ratio [(C1)/(A)] = 0.12, mass ratio [(C2)/(A)] = 0.35, mass ratio [(B)/(A)] = 0.23)
(Ingredients (amount))
Stearic acid-treated titanium oxide (component (A1)) *1 7 parts Silicone-treated zinc oxide (component (A3)) *2 19 parts Neopentyl glycol dicaprate (component (C1)) *3 3 parts Liquid isoparaffin (component (C2)) *4 7 parts Squalane (component (C2)) *5 2 parts Dimethylpolysiloxane (25 ° C. kinematic viscosity: 10 mm ² /s) (component (B)) *6 1 part Dimethylpolysiloxane (25 ° C. kinematic viscosity: 6 mm ² /s) (component (B)) *13 5 parts N-(hexadecyloxyhydroxypropyl)-N-hydroxyethylhexadecanamide *7 1.5 parts Polyoxyethylene / methylpolysiloxane copolymer (HLB: 4.5) *8 1.4 parts Dodecamethylpentasiloxane (25 ° C. kinematic viscosity: 2 mm ² /s) (component (D)) *9 35.1 parts Glycerin (86%) 1 part
Purified water remainder
Total 100 copies

Formulation Example 3 (W/O type external preparation, mass ratio [(C1)/(A)] = 0.97, mass ratio [(B)/(A)] = 0.27)
(Ingredients (amount))
Octyltriethoxysilane-treated zinc oxide (component (A2)) *14 15 parts 2-ethylhexyl paramethoxycinnamate (component (C1)) *15 10 parts Neopentyl glycol dicaprate (component (C1)) *3 3 parts Isopropyl palmitate (component (C1)) *17 1.5 parts Dimethylpolysiloxane (25 ° C. kinematic viscosity: 6 mm ² /s) (component (B)) *13 4 parts 2,4-bis-[{4-(2-ethylhexyloxy)-2-hydroxy}-phenyl]-6-(4-methoxyphenyl)-1,3,5-triazine *16 2 parts Polyoxyethylene / methylpolysiloxane copolymer (HLB: 4.5) *8 0.8 parts Dodecamethylpentasiloxane (25 ° C. kinematic viscosity: 2 mm ² /s) (component (D)) *9 5 parts Decamethylcyclopentasiloxane (kinematic viscosity at 25°C: 4 mm ² /s) (component (D)) *18 28.7 parts Silicone-coated talc *11 2 parts Ethanol 11 parts 1,3-butylene glycol 2 parts
Purified water remainder
Total 100 copies

Formulation Example 4 (W/O type external preparation, mass ratio [(C2)/(A)] = 0.41, mass ratio [(B)/(A)] = 0.14)
(Ingredients (amount))
Stearic acid-treated titanium oxide (component (A1)) *1 10 parts Silicone-treated zinc oxide (component (A3)) *2 19 parts Liquid isoparaffin (component (C2)) *4 10 parts Squalane (component (C2)) *5 2 parts Dimethylpolysiloxane (25 ° C. kinematic viscosity: 10 mm ² /s) (component (B)) *6 1 part Dimethylpolysiloxane (25 ° C. kinematic viscosity: 6 mm ² /s) (component (B)) *13 3 parts N- (hexadecyloxyhydroxypropyl) -N- hydroxyethylhexadecanamide *7 1.5 parts Polyoxyethylene / methylpolysiloxane copolymer (HLB: 4.5) *8 1.4 parts Dodecamethylpentasiloxane (25 ° C. kinematic viscosity: 2 mm ² /s) (component (D)) *9 35.1 parts Glycerin (86%) 1 part
Purified water remainder
Total 100 copies

Formulation Example 5 (O/W type topical preparation, mass ratio [(C1)/(A)] = 3.0, mass ratio [(B)/(A)] = 0.25)
(Ingredients (amount))
Stearic acid-treated titanium dioxide (ingredient (A1)) *19 4 parts Isopropyl palmitate (ingredient (C1)) *17 4 parts 2-ethylhexyl paramethoxycinnamate (ingredient (C1)) *15 8 parts Dimethylpolysiloxane (25 ° C kinematic viscosity: 10 mm ² /s) (ingredient (B)) *6 1 part 2,4-bis-[{4-(2-ethylhexyloxy)-2-hydroxy}-phenyl]-6-(4-methoxyphenyl)-1,3,5-triazine *16 1 part Cetyl alcohol *20 0.2 parts Glyceryl monostearate *21 0.3 parts Isoceteth-20 *22 0.03 parts (Acrylates / alkyl acrylate (C10-30)) crosspolymer *23 0.2 parts (Acrylates / alkyl acrylate (C10-30)) crosspolymer *24 0.2 parts EDTA-2Na 0.01 parts phenoxyethanol 0.5 parts potassium hydroxide (48%) 0.4 parts ethanol 5 parts
Purified water remainder
Total 100 copies

Formulation Example 6 (O/W type topical preparation, mass ratio [(C1)/(A)] = 3.5, mass ratio [(B)/(A)] = 0.25)
(Ingredients (amount))
Octyltriethoxysilane-treated titanium oxide (component (A2)) * 25 4 parts Isopropyl palmitate (component (C1)) * 17 4 parts 2-ethylhexyl paramethoxycinnamate (component (C1)) * 15 8 parts 2,4,6-tris [4- (2-ethylhexyloxycarbonyl) anilino] -1,
3,5-triazine (component (C1)) *26 2 parts Dimethylpolysiloxane (25°C kinematic viscosity: 10 ^mm2 /s) (component (B)) *6 1 part 2,4-bis-[{4-(2-ethylhexyloxy)-2-hydroxy}-phenyl]-6-(4-methoxyphenyl)-1,3,5-triazine *16 2 parts Cetyl alcohol *20 0.2 parts Glyceryl monostearate *21 0.3 parts Isoceteth-20 *22 0.03 parts Polyoxyethylene sorbitan monostearate *27 0.1 parts (Acrylates / alkyl acrylate (C10-30)) crosspolymer *23 0.2 parts (Acrylates / alkyl acrylate (C10-30)) crosspolymer *24 0.2 parts Light liquid isoparaffin (component (D)) *28 1 part EDTA-2Na 0.01 parts Phenoxyethanol 0.5 parts 1,3-butylene glycol 5 parts Potassium hydroxide (48%) 0.6 parts Ethanol 5 parts
Purified water remainder
Total 100 copies

Formulation Example 7 (O/W type topical preparation, mass ratio [(C1)/(A)] = 1.5, mass ratio [(B)/(A)] = 0.50)
(Ingredients (amount))
Stearic acid-treated titanium dioxide (component (A1)) *19 8 parts Isononyl isononanoate (component (C1)) *30 7.6 parts Neopentyl glycol dicaprate (component (C1)) *3 4 parts Dimethylpolysiloxane (25°C kinematic viscosity: 6 ^mm2 /s) (component (B)) *13 4 parts Sorbitan monostearate *29 0.7 parts Polyoxyethylene sorbitan monostearate *27 1 part Stearyl alcohol 1 part (Acrylates / alkyl acrylate (C10-30)) crosspolymer *23 0.07 parts (Acrylates / alkyl acrylate (C10-30)) crosspolymer *24 0.25 parts Potassium hydroxide (48%) 0.4 parts 1,3-butylene glycol 8 parts EDTA-2Na 0.02 parts
Purified water remainder
Total 100 copies

From Table 7, it can be seen that Examples 13 to 19 have an adhesion inhibitory effect when the topical preparations shown in Formulation Examples 1 to 7 are applied.
Furthermore, compared to Reference Examples 1 to 4, the topical preparations used in Examples 13 to 19 contain component (B), and therefore have a good feel (touch) when used.

The adhesion prevention method of the present invention is highly effective in preventing the adhesion of atmospheric hazardous substances, making it particularly useful as a method for preventing the adhesion of atmospheric hazardous substances to the skin.

1: Sample to be evaluated 2: Support 3: Mesh sieve 4: Air hazardous substance to be evaluated 5: Blower

Claims (8)

A method for suppressing adhesion of atmospheric hazardous substances to the skin by applying an external preparation to the skin, the method comprising:
The topical preparation contains the following components (A), (B), and (C), wherein component (C) is ester oil (C1), the mass ratio of the content of component (B) to the content of component (A) in the topical preparation [(B)/(A)] is 0.01 or more and 0.85 or less, and the mass ratio of the total content of components (B) and (C1) to the content of component (A) in the topical preparation [[(B)+(C1)]/(A)] is 0.1 or more and 4 or less,
The amount of component (A) applied to the skin is 0.03 mg/cm2 or more ^.
A method for suppressing the adhesion of harmful substances to the atmosphere.
Component (A): A hydrophobized metal oxide having an average primary particle diameter d _A of 5 nm to 50 nm, the metal oxide being at least one selected from titanium oxide and zinc oxide; Component (B): A non-volatile silicone oil; and Component (C): A non-volatile oil other than Component (B). 2. The method for inhibiting adhesion of atmospheric hazardous substances according to claim 1 , wherein the content of component (A) in the topical preparation is 1% by mass or more and 40% by mass or less. 3. The method for inhibiting adhesion of atmospheric hazardous substances according to claim 1 or 2 , wherein the amount of component (A) applied to the skin is 0.8 mg/ ^cm2 or less. 4. The method for inhibiting adhesion of atmospheric hazardous substances according to claim 1, wherein component (A) is one or more selected from the following components (A1), (A2), and (A3):
Component (A1): A fatty acid-treated metal oxide having an average primary particle diameter d _A of 5 nm or more and 50 nm or less. Component (A2): An alkylalkoxysilane-treated metal oxide having an average primary particle diameter d _A of 5 nm or more and 50 nm or less. Component (A3): A silicone-treated metal oxide having an average primary particle diameter d _A of 5 nm or more and 50 nm or less. 5. A method for suppressing adhesion of atmospheric hazardous substances as described in claim 4, wherein the mass ratio [(B)/[(A1)+(A2)+(A3)]] of the content of component (B) to the total content of components (A1), (A2) and (A3 ) in the topical preparation is 0.01 or more and 0.85 or less. 6. The method for suppressing adhesion of atmospheric hazardous substances according to claim 4 or 5 , wherein the total amount of components (A1), (A2) and (A3) applied to the skin is 0.03 mg/ ^cm2 or more. The method for suppressing adhesion of atmospheric hazardous substances according to any one of claims 4 to 6 , wherein the total content of components (A1), (A2), and (A3) in the topical preparation is 1% by mass or more and 40% by mass or less. 8. The method for suppressing adhesion of atmospheric hazardous substances according to claim 6 or 7 , wherein the total amount of components (A1), (A2) and (A3) applied to the skin is 0.8 mg/ ^cm2 or less.